Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Solomon, Crystal
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure	Terminated	2	136	Europe, Japan, US, RoW	Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan	Novartis Pharmaceuticals	Heart Failure	11/24	11/24
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy	Recruiting	1/2	192	Canada, US	Peanut SLIT-tablet, Placebo	ALK-Abelló A/S, Parexel	Peanut Allergy	01/26	02/26
RAPID, NCT04287621: Registry of Asthma Patients Initiating DUPIXENT®	Active, not recruiting	N/A	718	Europe, Canada, Japan, US	DUPIXENT®, dupilumab, REGN668, SAR231893	Regeneron Pharmaceuticals, Sanofi	Asthma	05/26	05/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Solomon, Crystal
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure	Terminated	2	136	Europe, Japan, US, RoW	Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan	Novartis Pharmaceuticals	Heart Failure	11/24	11/24
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy	Recruiting	1/2	192	Canada, US	Peanut SLIT-tablet, Placebo	ALK-Abelló A/S, Parexel	Peanut Allergy	01/26	02/26
RAPID, NCT04287621: Registry of Asthma Patients Initiating DUPIXENT®	Active, not recruiting	N/A	718	Europe, Canada, Japan, US	DUPIXENT®, dupilumab, REGN668, SAR231893	Regeneron Pharmaceuticals, Sanofi	Asthma	05/26	05/26